Results Three hundred and twenty-five patients completed the study(162 in the losartan group and 163 in the irbesartan group).
结果随机人选351例患者,325例完成试验,氯沙坦组162例,伊贝沙坦组163例。
参考来源 - 血管紧张素Ⅱ受体拮抗剂干预高血压患者尿酸代谢的对比研究·2,447,543篇论文数据，部分数据来源于NoteExpress
目的：观察伊贝沙坦对良性小动脉性肾硬化蛋白尿的效应。
Objective: To observe the effect of irbesartan on proteinuria in benign arteriolar nephrosclerosis patients.
目的为了探讨原发性高血压患者伊贝沙坦降压疗效的影响因素。
Objective to evaluate the risk factors of Irbesartan in treatment of essential hypertension and to explore individualized antihypertensive treatment.
目的探讨伊贝沙坦对原发性高血压(EH)患者血管内皮功能的保护作用。
Objective it is to discuss the protection of Irbesartan on endothelial function of blood vessel in patients with essential hypertension (EH).
药物名称： 伊贝沙坦 别名： 依比沙坦；厄贝沙坦；2-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1�1′-biphenyl]-4-yl]methyl]-1�3-diazaspiro[4.4]non-1-en-4-one； 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1�3-diazaspiro[4.4]non-1-en-4-one; 2-n-butyl-4-spirocyclopentane-1-[(2′-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one
应用推荐